[ 18 F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer-Reference-Cited by-同舟云学术

[ 18 F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer

Published:2019-04-12 Issue:6 Volume:34 Page:924-926
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord

Author:

Zee Sygrid¹,Vállez García David²^ORCID,Elsinga Philip H.²,Willemsen Antoon T.M.²,Boersma Hendrikus H.²³,Gerritsen Marleen J.J.¹,Spikman Jacoba M.¹,Laar Teus¹

Affiliation:

1. Department of NeurologyUniversity of Groningen, University Medical Center Groningen Groningen the Netherlands

2. Department of Nuclear Medicine and Molecular ImagingUniversity of Groningen, University Medical Center Groningen Groningen the Netherlands

3. Department of Clinical Pharmacy and PharmacologyUniversity Medical Center Groningen Groningen the Netherlands

Funder

Weston Brain Institute

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.27698

Reference7 articles.

1. Cholinergic Dysfunction in Parkinson’s Disease

2. In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses

3. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV

4. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV

5. Cholinergic system changes of falls and freezing of gain in Parkinson's disease;Bohnen NI;Ann Neurol.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholinergic deficiency in Parkinson’s disease patients with visual hallucinations;Brain;2024-06-12

2. Short-latency afferent inhibition as a biomarker of cholinergic degeneration compared to PET imaging in Parkinson's disease;Parkinsonism & Related Disorders;2024-04

3. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes;Brain;2024-03-04

4. Cholinergic innervation topography in GBA-associated de novo Parkinson’s disease patients;Brain;2023-09-25

5. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson’s disease;Brain;2023-07-05